Category Archives: LDK378 – Ceritinib from Novartis

Video on Alectinib

Here is a video discussing Alectinib and comparing it with Crizotinib and Ceritinib. He also mentioned an upcoming trial that is being planned that would compare various sequences of the drugs. http://www.onclive.com/conference-coverage/thoracic-2014/Dr-Govindan-on-the-Potential-for-Alectinib

Posted in Brain metastases, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Research, Resistance to treatment | Leave a comment

Ceritinib effective on brain mets.

ALK-inhibitor naïve patients treated with ceritinib experienced an overall response rate (ORR) of 72.3% and a median progression-free survival (PFS) of 18.4 months. In ALK inhibitor treated patients, the ORR was 56.4% and the median PFS was 6.9 months. In … Continue reading

Posted in Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Research | Leave a comment

Video on ALK inhibitor efficacy

By Dr. Jack West http://www.onclive.com/peer-exchange/nsclc-needs/Efficacy-of-Next-Generation-ALK-Inhibitors

Posted in AP26113 from Ariad, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Research | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CEP-37440, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, RXDX-101 by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

List of 8 ALK Inhibitors in trials

List of 8 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Pfizer – Crizotinib (2011 initial, 2013 final) Novartis – Ceritinib (2014 initial) FDA Breakthrough Status Chugai – Alectinib (approved in Japan in 2014) Ariad … Continue reading

Posted in AP26113 from Ariad, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, Regulatory applications & approvals, Research, RXDX-101 by Ignyta, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

Collaboration between Novartis and Bristol Meyers Squibb

A collaboration between Novartis and Bristol-Myers Squibb (BMS) has resulted in the establishment of several clinical trials combining the PD-1 inhibitor nivolumab (Opdivo) with targeted therapies against ALK (Ceritinib), c-MET, and T790M for patients with non-small cell lung cancer (NSCLC). … Continue reading

Posted in LDK378 - Ceritinib from Novartis, Lung cancer, Research | Leave a comment

5-6 minute video by OncLive

The discussion is about Ceritinib by Novartis and AP26113 by Ariad. The main speakers are Dr. Shaw and Dr. Cambidge. https://m.youtube.com/watch?v=vRHm7XTE3fw Seems like it was recorded in May or June 2014.

Posted in AP26113 from Ariad, Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Resistance to treatment, Side Effects | Leave a comment

GRACE conference in Boston

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online. PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 from Xcovrery | 1 Comment

Novartis announces positive results

Patients had progression free survival (PFS) of an average of 18 months when taking Novartis’ Zykadia (ceritinib) as their first ALK inhibitor for ALK+ Lung cancer. REMARKABLE! These patients had an objective response rate (ORR) of 72.3%. Zykadia achieved ORR … Continue reading

Posted in LDK378 - Ceritinib from Novartis | Leave a comment

Crizotinib / Ceritinib mutation study

Below is a link to a Cancer Discovery article, which found that biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations. In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T, and S1206Y mutations. However, they … Continue reading

Posted in Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Research, Resistance to treatment | Leave a comment